Operating Margin: 31.22%
Is the operating margin high or low?
The operating margin of 31.22% is in line with its 5-year average of 28.65%, near the high end of its 5-year range (22.56%–32.75%).
As of Sunday, June 28, 2026. 12.91% above its 12-month average of 27.65%.
EW Operating Margin
Reported quarterly operating margin; no daily interpolation.
EW Average Operating Margin Chart
EW Current vs Average Operating Margin Chart
EW Operating Margin Metrics
OPERATING MARGIN
31.22%
OPERATING MARGIN AVG TTM
27.65%
OPERATING MARGIN AVG 3Y
27.46%
OPERATING MARGIN AVG 5Y
28.65%
OPERATING MARGIN AVG 10Y
28.58%
OPERATING MARGIN AVG 15Y
26.29%
OPERATING MARGIN AVG 20Y
24.11%
CURRENT VS TTM AVG
+12.91%
CURRENT VS 3Y AVG
+13.69%
CURRENT VS 5Y AVG
+8.99%
CURRENT VS 10Y AVG
+9.24%
CURRENT VS 15Y AVG
+18.77%
CURRENT VS 20Y AVG
+29.49%
EW Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 31.22% | 27.65% | 27.46% | 28.65% |
| Cencora, Inc. (COR)vs › | $55.67B | 1.28% | 1.08% | 1.06% | 1.09% |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | 0.92% | 0.79% | 0.40% | -0.13% |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 10.61% | 11.84% | 11.67% | 10.68% |
| Humana Inc. (HUM)vs › | $46.08B | 1.01% | 1.25% | 2.37% | 3.27% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 31.63% | 30.27% | 29.30% | 28.64% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 24.32% | 26.52% | 32.61% | 38.03% |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 20.12% | 17.76% | 16.30% | 14.57% |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 21.50% | 22.07% | 21.88% | 20.79% |
| Medline Inc. (MDLN)vs › | $32.87B | 7.04% | 8.25% | 6.70% | 6.70% |
Operating Efficiency
Gross Margin
78.0%
Operating Margin
31.2%
Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Operating Margin FAQ
- What is the operating margin for Edwards Lifesciences Corporation (EW)?
- The operating margin for EW stock is 31.22%.
- Is Edwards Lifesciences Corporation's operating margin high or low?
- The operating margin of 31.22% is in line with its 5-year average of 28.65%, near the high end of its 5-year range (22.56%–32.75%).
- What is the TTM average operating margin for Edwards Lifesciences Corporation (EW)?
- The TTM average operating margin for EW stock is 27.65%.
- What is the 3Y average operating margin for Edwards Lifesciences Corporation (EW)?
- The 3Y average operating margin for EW stock is 27.46%.
- What is the 5Y average operating margin for Edwards Lifesciences Corporation (EW)?
- The 5Y average operating margin for EW stock is 28.65%.
- What is the 10Y average operating margin for Edwards Lifesciences Corporation (EW)?
- The 10Y average operating margin for EW stock is 28.58%.
- What is the 15Y average operating margin for Edwards Lifesciences Corporation (EW)?
- The 15Y average operating margin for EW stock is 26.29%.
- What is the 20Y average operating margin for Edwards Lifesciences Corporation (EW)?
- The 20Y average operating margin for EW stock is 24.11%.
EW Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2026-03-31 | 31.22% |
| 2025-12-31 | 23.59% |
| 2025-09-30 | 27.37% |
| 2025-06-30 | 28.12% |
| 2025-03-31 | 27.95% |
| 2024-12-31 | 22.56% |
| 2024-09-30 | 25.89% |
| 2024-06-30 | 26.32% |
| 2024-03-31 | 26.73% |
| 2023-12-31 | 28.17% |
| 2023-09-30 | 27.87% |
| 2023-06-30 | 28.61% |
| 2023-03-31 | 27.60% |
| 2022-12-31 | 30.37% |
| 2022-09-30 | 32.39% |
| 2022-06-30 | 31.18% |
| 2022-03-31 | 32.49% |
| 2021-12-31 | 27.21% |
| 2021-09-30 | 31.08% |
| 2021-06-30 | 32.75% |
| 2021-03-31 | 32.12% |
| 2020-12-31 | 30.40% |
| 2020-09-30 | 30.77% |
| 2020-06-30 | 23.91% |
| 2020-03-31 | 32.03% |
| 2019-12-31 | 28.71% |
| 2019-09-30 | 26.19% |
| 2019-06-30 | 24.91% |
| 2019-03-31 | 30.37% |
| 2018-12-31 | 29.67% |
| 2018-09-30 | 28.17% |
| 2018-06-30 | 29.90% |
| 2018-03-31 | 29.57% |
| 2017-12-31 | 27.17% |
| 2017-09-30 | 26.54% |
| 2017-06-30 | 30.27% |
| 2017-03-31 | 34.82% |
| 2016-12-31 | 27.21% |
| 2016-09-30 | 26.89% |
| 2016-06-30 | 23.79% |
| 2016-03-31 | 28.95% |
| 2015-12-31 | 26.03% |
| 2015-09-30 | 25.31% |
| 2015-06-30 | 23.80% |
| 2015-03-31 | 28.02% |
| 2014-12-31 | 22.70% |
| 2014-09-30 | 21.32% |
| 2014-06-30 | 20.74% |
| 2014-03-31 | 17.90% |
| 2013-12-31 | 22.65% |
| 2013-09-30 | 20.44% |
| 2013-06-30 | 23.65% |
| 2013-03-31 | 22.05% |
| 2012-12-31 | 25.84% |
| 2012-09-30 | 21.12% |
| 2012-06-30 | 19.88% |
| 2012-03-31 | 18.75% |
| 2011-12-31 | 20.11% |
| 2011-09-30 | 14.51% |
| 2011-06-30 | 17.46% |
| 2011-03-31 | 19.38% |
| 2010-12-31 | 20.54% |
| 2010-09-30 | 19.32% |
| 2010-06-30 | 20.15% |
| 2010-03-31 | 18.41% |
| 2009-12-31 | 18.58% |
| 2009-09-30 | 17.32% |
| 2009-06-30 | 18.63% |
| 2009-03-31 | 17.45% |
| 2008-12-31 | 17.73% |
| 2008-09-30 | 14.59% |
| 2008-06-30 | 16.09% |
| 2008-03-31 | 11.69% |
| 2007-12-31 | 15.49% |
| 2007-09-30 | 14.00% |
| 2007-06-30 | 17.28% |
| 2007-03-31 | 16.89% |
| 2006-12-31 | 16.23% |
| 2006-09-30 | 16.25% |
| 2006-06-30 | 17.10% |
| 2006-03-31 | 25.68% |
| 2005-12-31 | 18.90% |
| 2005-09-30 | 16.65% |
| 2005-06-30 | 17.82% |
| 2005-03-31 | 17.10% |
| 2004-12-31 | 16.79% |
| 2004-09-30 | 15.70% |
| 2004-06-30 | 17.26% |
| 2004-03-31 | 9.96% |
| 2003-12-31 | 17.45% |
| 2003-09-30 | 15.48% |
| 2003-06-30 | 14.28% |
| 2003-03-31 | 15.53% |
| 2002-12-31 | 15.26% |
| 2002-09-30 | -24.67% |
| 2002-06-30 | 18.00% |
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian